Key statistics
On Friday, Aptargroup Inc (ATR:NYQ) closed at 134.31, -18.24% below its 52-week high of 164.28, set on Jul 24, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 127.53 |
|---|---|
| High | 135.99 |
| Low | 127.53 |
| Bid | -- |
| Offer | 144.00 |
| Previous close | 123.98 |
| Average volume | 679.22k |
|---|---|
| Shares outstanding | 65.62m |
| Free float | 64.92m |
| P/E (TTM) | 19.88 |
| Market cap | 8.14bn USD |
| EPS (TTM) | 6.24 USD |
| Annual div (ADY) | 1.92 USD |
|---|---|
| Annual div yield (ADY) | 1.55% |
| Div ex-date | Feb 04 2026 |
| Div pay-date | Feb 25 2026 |
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
More ▼
- Aptar Reports Fourth Quarter and Annual 2025 Results
- Aptar Declares Quarterly Dividend and Announces 2026 Annual Meeting Details
- Aptar Again Recognized with Prestigious ‘A’ Score on the CDP Climate Change Assessment
- Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate
- Aptar’s Eye Care Solutions Designed to Improve Dosing Precision, Including Newest Technology, Beat the Blink™
- Aptar Announces 2026 Quarterly Conference Call Dates
- Aptar Digital Health and ŌURA Collaborate to Advance Migraine Insights by Connecting Migraine Buddy® with Oura Ring
- Aptar to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
- Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)
- Aptar Named One of America’s Most Responsible Companies by Newsweek for the Seventh Consecutive Year
More ▼
